Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer
Public ClinicalTrials.gov record NCT00014222. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Adjuvant Trial Of Sequenced EC + Filgrastim + Epoetin Alfa Followed By Paclitaxel Versus Sequenced AC Followed By Paclitaxel Versus CEF As Therapy For Premenopausal Women And Early Postmenopausal Women Who Have Had Potentially Curative Surgery For Node Positive Or High Risk Node Negative Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: 1. . To compare the effects on breast cancer of three different combinations of drugs which are commonly used to treat this disease. 2. . It is not yet known which treatment regimen is most effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy given with or without epoetin alfa in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer.
Study identification
- NCT ID
- NCT00014222
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 2,104 participants
Conditions and interventions
Conditions
Interventions
- epoetin alfa Biological
- filgrastim Biological
- cyclophosphamide Drug
- doxorubicin hydrochloride Drug
- epirubicin hydrochloride Drug
- fluorouracil Drug
- paclitaxel Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- Up to 60 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 4, 2000 (Actual)
- Primary completion
- Feb 10, 2014 (Actual)
- Completion
- Mar 17, 2014 (Actual)
- Last update posted
- Oct 5, 2020
2000 – 2014
United States locations
- U.S. sites
- 44
- U.S. states
- 25
- U.S. cities
- 42
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sparks-Arkansas Oklahoma Cancer Treatment Centre | Fort Smith | Arkansas | 72901 | — |
| Hematology Oncology Services of Arkansas | Little Rock | Arkansas | 72205 | — |
| Scripps Cancer Center | La Jolla | California | 92037 | — |
| University of Colorado Cancer Centre | Aurora | Colorado | 80010-0510 | — |
| Greenwich Hospital - Bendheim Cancer Center | Greenwich | Connecticut | 06830 | — |
| Sibley Memorial Hospital, Oncology Research | Washington D.C. | District of Columbia | 20016 | — |
| Comprehensive Cancer Care Centre at Boca Raton | Boca Raton | Florida | 33428 | — |
| University of Florida | Gainesville | Florida | 32610-0277 | — |
| Florida Oncology Associates | Orange Park | Florida | 32073 | — |
| The University of Chicago Medical Center | Chicago | Illinois | 60637-1470 | — |
| Therapy Associates, Inc., Hematology/Oncology | Evansville | Indiana | 47715 | — |
| Lexington Oncology Assts./Central Baptist Hospital | Lexington | Kentucky | 40503 | — |
| Consultants in Blood Disorders and Cancer | Louisville | Kentucky | 40207 | — |
| CHRISTUS Schumpert Medical Center - Hem/Onc Clinic | Shreveport | Louisiana | 71101 | — |
| Willis-Knighton Cancer Center | Shreveport | Louisiana | 71103-3 | — |
| Maine Center for Cancer Medicine and Blood Disorders | Scarborough | Maine | 04074-9308 | — |
| Maine General Medical Center | Waterville | Maine | 04901 | — |
| Suburban Hospital Cancer Program | Bethesda | Maryland | 20817 | — |
| Associates in Oncology/Hematology | Rockville | Maryland | 20850 | — |
| Saint Joseph Medical Center, Cancer Care Program | Towson | Maryland | 21204 | — |
| Baystate Regional Cancer Program | Springfield | Massachusetts | 01107 | — |
| St. Luke's Cancer Care Centre | Duluth | Minnesota | 55802 | — |
| University of Minnesota Cancer Centre | Minneapolis | Minnesota | 55455 | — |
| Columbia-Capitol Comprehensive Care Clinics | Jefferson City | Missouri | 65109 | — |
| Saint Louis University Hospital | St Louis | Missouri | 63110-0250 | — |
| Nebraska Methodist Hospital | Omaha | Nebraska | 68114 | — |
| Creighton University Cancer Centre | Omaha | Nebraska | 68131 | — |
| Advanced Oncology Associates | Armonk | New York | 10504 | — |
| Queens Medical Associates, PC | Fresh Meadows | New York | 11366 | — |
| Winthrop University Hospital Onc/Hem | Mineola | New York | 11501 | — |
| Hematology Oncol. Associates Rockland | Nyack | New York | 10960 | — |
| University of Rochester | Rochester | New York | 14642 | — |
| Staten Island University Hospital | Staten Island | New York | 10305 | — |
| Our Lady of Mercy Medical Center | The Bronx | New York | 10466 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| ECU School of Medicine, Leo Jenkins Cancer Center | Greenville | North Carolina | 27858 | — |
| Oncology/Hematology Care, Inc. | Cincinnati | Ohio | 45242 | — |
| Pottstown Memorial Regional Cancer Centre | Pottstown | Pennsylvania | 19464 | — |
| Santee Hematology Oncology | Sumter | South Carolina | 29150 | — |
| University Oncology and Hematology Associates | Chattanooga | Tennessee | 37404 | — |
| Lone Star Oncology Consultants, PA | Austin | Texas | 78759 | — |
| Center for Oncology Research and Treatment | Dallas | Texas | 75230 | — |
| Northern Utah Associates | Ogden | Utah | 84403 | — |
| Arlington-Fairfax Hematology Oncology P.C. | Arlington | Virginia | 22205 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00014222, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 5, 2020 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00014222 live on ClinicalTrials.gov.